Antioxidative action of the novel calcium channel antagonist mibefradil on low-density lipoproteins

European Journal of Clinical Pharmacology

Volumn 54, Issue 8, 1998, Pages 603-607

  Leonhardt, W ^a   Lange, M ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b ASTA MEDICA AG   (Germany)

Author keywords

Calcium channel blocker; Low density lipoprotein oxidation; Mibefradil

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; LOW DENSITY LIPOPROTEIN; MIBEFRADIL;

ANTIOXIDANT ACTIVITY; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; LIPID PEROXIDATION; NORMAL HUMAN; PRIORITY JOURNAL;

AMIDINES; ANTIOXIDANTS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIPOPROTEINS, LDL; MIBEFRADIL; MOLECULAR STRUCTURE; OXIDANTS; TETRAHYDRONAPHTHALENES;

EID: 0031741760     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050521     Document Type: Article

References (31)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low density lipoproteins that increase its atherogenicity. N Engl J Med 320: 915-924
2. Esterbauer H, Striegl G, Puhl H, Rotheneder M (1989) Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6: 67-75
3. Cominacini L, Garbin U, Pastorino AM, Davoli A, Campagnola M, De Santis A, Pasini C, Faccini GB, Trevisan MT, Bertozzo L, Pasini F, Lo Cascio V (1993) Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Atherosclerosis 99: 63-70
4. De Rijke J, Verwey HF, Vogelezang CJM, van der Velde EA, Princen HMG, van der Laarse A, Bruschke AVG, van Berkel TJC (1995) Enhanced susceptibility of low-density lipoproteins to oxidation in coronary bypass patients with progression of atherosclerosis. Clin Chim Acta 243: 137-149
5. Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A (1992) Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339: 1183-1186
6. Anderson TJ, Meredith IT, Charbonneau F, Yeung AC, Frei B, Selwyn AP, Ganz P (1996) Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 93: 1647-1650
7. Noguchi N, Iwaki Y, Takahashi M, Komuro E, Kato Y, Tamura K, Cynshi O, Kodama T, Niki E (1997) 2.3-Dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: design and evaluation as a novel radical-scavenging antioxidant against lipid peroxidation. Arch Biochem Biophys 342: 236-243
8. Leonhardt W, Kurktschiev T, Meissner D, Lattke P, Abletshauser C, Weidinger G, Jaross W, Hanefeld M (1997) Effects of fluvaslatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals. Eur J Clin Pharmacol 53: 65-69
9. Leonhardt W, Bergmann R, Hanefeld M (1997) Initiation of LDL oxidation by copper ions or AAPH yields different kinetic parameters which are correlated. Clin Chim Acta 259: 195-197
10. Pietzsch J, Subat S, Nitzsche S, Leonhardt W, Schentke KU, Hanefeld M (1995) Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim Biophys Acta Lipids and Lipid Metabolism 1254: 77-88
11. Nourooz-Zadeh J, Tajaddinisarmadi J, Wolff SP (1994) Measurement of plasma hydroperoxide concentrations by the ferrous oxidation xylenol orange assay in conjunction with triphenylphosphine. Anal Biochem 220: 403-409
12. Brogden RN, Markham A (1997) Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris. Drugs 54: 775-793
13. Lupo E, Locher R, Weisser B, Vetter W (1994) In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol. Biochem Biophys Res Commun 203: 1803-1808
14. Yue TL, Wang XK, Gu JL, Ruffolo RR, Feuerstein GZ (1995) Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 273: 1442-1449
15. Napoli C, Chiariello M, Palumbo G, Ambrosio G (1996) Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals. Cardiovasc Drugs Ther 10: 417-424
16. Iuliano L, Colavita AR, Camastra C, Bello V, Quintarelli C, Alessandroni M, Piovella F, Violi F (1996) Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol 119: 1438-1446
17. Grignaffini P, Rasario C, Fumagalli R (1996) Lercanidipine, a new calcium antagonist, protects low density lipoprotein from oxidation. 66th Congress of the EAS, Florence, July 13-17
18. ++-mediated oxidation of low-density lipoprotein. Biochem Pharmacol 51: 1277-1282
19. Aruoma OI (1996) Peroxyl radical scavenging activity of the antihypertensive drug carvedilol. Toxicol in Vitro 10: 625-629
20. Aruoma OI (1997) Scavenging of hypochlorous acid by carvedilol and ebselen in vitro. Gen Pharmacol 28: 269-272
21. Seifert T, Zschornig O, Arnhold J, Arnold K (1997) Beta-blockers inhibit the modification of low-density lipoproteins by sodium hypochlorite in vitro. Chem Phys Lipids 85: 13-21
22. Karmansky I, Gruener N (1997) A mechanism of antioxidant activity of calcium antagonist verapamil against LDL oxidation. Clin Chim Acta 259: 177-182
23. Lesnik P, Dachet C, Petit L, Moreau M, Griglio S, Brudi P, Chapman MJ (1997) Impact of a combination of a calcium antagonist and a beta-blocker on cell- and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells. Arterioscler Thromb Vasc Biol 17: 979-988
24. Beaughard M, Chevalier A, Dureng G, Leboeuf J, Massingham R, Mazur A, Rayssiguier Y, Winslow E (1997) In vitro calcium antagonistic and antioxidant effects of Org 13061 and its enantiomers, new potential antiatherosclerotic compounds. Fundam Clin Pharmacol 11: 416-426
25. Bartosz M, Kedziora J, Bartosz G (1997) Antioxidant and prooxidant properties of captopril and enalapril. Free Radic Biol Med 23: 729-735
26. Skerjanec A, Tawfik S, Tam YK (1996) Nonlinear pharmacokinetics of mibefradil in the dog. J Pharm Sci 85: 189-192
27. Mibefradil. Data sheet. ASTA Medica AWD GmbH Frankfurt
28. Schmitt R, Clozel J-P, Iberg N, Bühler FR (1995) Mibefradil prevents neointima formation after vascular injury in rats. Arterioscler Thromb Vasc Biol 15: 1161-1165
29. Mulder P, Richard V, Compagnon P, Henry JP, Lallemand F, Clozel JP, Koen R, Mace B, Thuillez C (1997) Increased survival after long-term treatment with mibefradil a selective T-channel calcium antagonist in heart failure. J Am Coll Cardiol 29: 416-421
30. Braun S, van der Wall EE, Emanuelsson H, Kobrin I (1996) Effects of a new calcium antagonist mibefradil (Ro 40-5967) on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol 27: 317-322
31. Tzivoni D, Kadr H, Braat S, Rutsch W, Ramires JA, Kobrin I (1997) Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily ischemia. Results of a multicenter, placebo-controlled trial. Circulation 96: 2557-2564